Robert J. Grun

Array ( [id] => 9989627 [patent_doc_number] => 09034829 [patent_country] => US [patent_kind] => B1 [patent_issue_date] => 2015-05-19 [patent_title] => 'pH-sensitive polymer-drug conjugates for targeted delivery of therapeutics' [patent_app_type] => utility [patent_app_number] => 13/663114 [patent_app_country] => US [patent_app_date] => 2012-10-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 20 [patent_no_of_words] => 8439 [patent_no_of_claims] => 5 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 71 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13663114 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9670445 [patent_doc_number] => 20140234308 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-21 [patent_title] => 'TREATMENT OF BREAST CANCER WITH COMPANION DIAGNOSTIC' [patent_app_type] => utility [patent_app_number] => 14/351825 [patent_app_country] => US [patent_app_date] => 2012-10-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 12 [patent_figures_cnt] => 12 [patent_no_of_words] => 22405 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 7 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14351825 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9735905 [patent_doc_number] => 20140271618 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-18 [patent_title] => 'ANTIBODIES TO CARCINOEMBRYONIC ANTIGEN-RELATED CELL ADHESION MOLECULE (CEACAM)' [patent_app_type] => utility [patent_app_number] => 14/350970 [patent_app_country] => US [patent_app_date] => 2012-10-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 22 [patent_figures_cnt] => 22 [patent_no_of_words] => 23127 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14350970 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9698609 [patent_doc_number] => 20140248294 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-09-04 [patent_title] => 'WNT4 AND MED12 FOR USE IN THE DIAGNOSIS AND TREATMENT OF TUMOR DISEASES' [patent_app_type] => utility [patent_app_number] => 14/349830 [patent_app_country] => US [patent_app_date] => 2012-10-05 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 5 [patent_figures_cnt] => 5 [patent_no_of_words] => 15452 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14349830 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8732683 [patent_doc_number] => 20130078252 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-28 [patent_title] => 'COMBINATION TREATMENTS COMPRISING C-MET ANTAGONISTS AND B-RAF ANTAGONISTS' [patent_app_type] => utility [patent_app_number] => 13/622878 [patent_app_country] => US [patent_app_date] => 2012-09-19 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 35 [patent_figures_cnt] => 35 [patent_no_of_words] => 46233 [patent_no_of_claims] => 43 [patent_no_of_ind_claims] => 26 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13622878 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10555614 [patent_doc_number] => 09279812 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2016-03-08 [patent_title] => 'Neuregulin-1-based prognosis and therapeutic stratification of colorectal cancer' [patent_app_type] => utility [patent_app_number] => 14/343071 [patent_app_country] => US [patent_app_date] => 2012-09-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 36 [patent_figures_cnt] => 53 [patent_no_of_words] => 17186 [patent_no_of_claims] => 8 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 146 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14343071 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8659107 [patent_doc_number] => 20130039936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-14 [patent_title] => 'IMMUNOGENIC POTE PEPTIDES AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/610421 [patent_app_country] => US [patent_app_date] => 2012-09-11 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 20377 [patent_no_of_claims] => 23 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13610421 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8744568 [patent_doc_number] => 20130084285 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-04-04 [patent_title] => 'TREATMENT WITH ANTI-ALPHA2 INTEGRIN ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 13/593285 [patent_app_country] => US [patent_app_date] => 2012-08-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 10 [patent_figures_cnt] => 10 [patent_no_of_words] => 31089 [patent_no_of_claims] => 11 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13593285 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8696928 [patent_doc_number] => 20130058936 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'BISPECIFIC ANTIBODIES SPECIFIC FOR T-CELL ACTIVATING ANTIGENS AND A TUMOR ANTIGEN AND METHODS OF USE' [patent_app_type] => utility [patent_app_number] => 13/591024 [patent_app_country] => US [patent_app_date] => 2012-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 19 [patent_figures_cnt] => 19 [patent_no_of_words] => 42541 [patent_no_of_claims] => 21 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13591024 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8696927 [patent_doc_number] => 20130058937 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-03-07 [patent_title] => 'Bispecific antigen binding molecules' [patent_app_type] => utility [patent_app_number] => 13/591028 [patent_app_country] => US [patent_app_date] => 2012-08-21 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 38 [patent_figures_cnt] => 38 [patent_no_of_words] => 37514 [patent_no_of_claims] => 41 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13591028 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8659077 [patent_doc_number] => 20130039907 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-02-14 [patent_title] => 'METHODS OF TREATING HEMATOLOGICAL PROLIFERATIVE DISORDERS BY TARGETING EPHA3 EXPRESSED ON ABERRANT VASCULATURE IN BONE MARROW' [patent_app_type] => utility [patent_app_number] => 13/571827 [patent_app_country] => US [patent_app_date] => 2012-08-10 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 2 [patent_figures_cnt] => 2 [patent_no_of_words] => 14851 [patent_no_of_claims] => 22 [patent_no_of_ind_claims] => 9 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13571827 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9983132 [patent_doc_number] => 09028836 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-05-12 [patent_title] => 'Globo H and related anti-cancer vaccines with novel glycolipid adjuvants' [patent_app_type] => utility [patent_app_number] => 13/568510 [patent_app_country] => US [patent_app_date] => 2012-08-07 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 18 [patent_figures_cnt] => 21 [patent_no_of_words] => 17777 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 52 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13568510 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9685842 [patent_doc_number] => 20140242607 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-08-28 [patent_title] => 'ANTIBODY FOR DETECTING EPITHELIAL OVARIAN CANCER MARKER AND METHOD FOR DIAGNOSING EPITHELIAL OVARIAN CANCER' [patent_app_type] => utility [patent_app_number] => 14/234871 [patent_app_country] => US [patent_app_date] => 2012-07-26 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 8 [patent_figures_cnt] => 8 [patent_no_of_words] => 16902 [patent_no_of_claims] => 16 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14234871 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8638062 [patent_doc_number] => 20130029865 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-31 [patent_title] => 'Stromal Antigen 2 (STAG2) Compositions and Methods' [patent_app_type] => utility [patent_app_number] => 13/547966 [patent_app_country] => US [patent_app_date] => 2012-07-12 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 28 [patent_figures_cnt] => 28 [patent_no_of_words] => 14114 [patent_no_of_claims] => 17 [patent_no_of_ind_claims] => 4 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13547966 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 8617311 [patent_doc_number] => 20130022623 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2013-01-24 [patent_title] => 'ANTIBODIES THAT SPECIFICALLY BIND TO TIM3' [patent_app_type] => utility [patent_app_number] => 13/538778 [patent_app_country] => US [patent_app_date] => 2012-06-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 9 [patent_figures_cnt] => 9 [patent_no_of_words] => 23631 [patent_no_of_claims] => 39 [patent_no_of_ind_claims] => 17 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 13538778 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9596727 [patent_doc_number] => 20140193408 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-10 [patent_title] => 'SOLUBLE PROTEINS FOR USE AS THERAPEUTICS' [patent_app_type] => utility [patent_app_number] => 14/126223 [patent_app_country] => US [patent_app_date] => 2012-06-15 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 4 [patent_figures_cnt] => 4 [patent_no_of_words] => 27412 [patent_no_of_claims] => 45 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14126223 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 10149062 [patent_doc_number] => 09181340 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2015-11-10 [patent_title] => 'TEM8 antibodies, conjugates thereof, and their use' [patent_app_type] => utility [patent_app_number] => 14/126372 [patent_app_country] => US [patent_app_date] => 2012-06-13 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 26 [patent_figures_cnt] => 59 [patent_no_of_words] => 40746 [patent_no_of_claims] => 37 [patent_no_of_ind_claims] => 1 [patent_words_short_claim] => 134 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14126372 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9616989 [patent_doc_number] => 20140206846 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-07-24 [patent_title] => 'Dual Targeting' [patent_app_type] => utility [patent_app_number] => 14/122758 [patent_app_country] => US [patent_app_date] => 2012-05-29 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 14 [patent_figures_cnt] => 14 [patent_no_of_words] => 11883 [patent_no_of_claims] => 24 [patent_no_of_ind_claims] => 5 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14122758 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 9396108 [patent_doc_number] => 20140093514 [patent_country] => US [patent_kind] => A1 [patent_issue_date] => 2014-04-03 [patent_title] => 'MAGEA3 BINDING ANTIBODIES' [patent_app_type] => utility [patent_app_number] => 14/123593 [patent_app_country] => US [patent_app_date] => 2012-05-23 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 16 [patent_figures_cnt] => 16 [patent_no_of_words] => 36219 [patent_no_of_claims] => 13 [patent_no_of_ind_claims] => 2 [patent_words_short_claim] => 0 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => publication [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14123593 [rel_patent_id] =>[rel_patent_doc_number] =>)

Array ( [id] => 11612583 [patent_doc_number] => 09650433 [patent_country] => US [patent_kind] => B2 [patent_issue_date] => 2017-05-16 [patent_title] => 'Modified glycoproteins' [patent_app_type] => utility [patent_app_number] => 14/118269 [patent_app_country] => US [patent_app_date] => 2012-05-18 [patent_effective_date] => 0000-00-00 [patent_drawing_sheets_cnt] => 13 [patent_figures_cnt] => 19 [patent_no_of_words] => 31724 [patent_no_of_claims] => 14 [patent_no_of_ind_claims] => 3 [patent_words_short_claim] => 23 [patent_maintenance] => 1 [patent_no_of_assignments] => 0 [patent_current_assignee] =>[type] => patent [pdf_file] =>[firstpage_image] =>[orig_patent_app_number] => 14118269 [rel_patent_id] =>[rel_patent_doc_number] =>)